Business Context and Reporting Period
This Form 8-K is a current report filed by ReShape Lifesciences Inc. (not Vyome Holdings, Inc.) on March 17, 2022. The filing serves to announce preliminary financial results for the fiscal year ended December 31, 2021. The company is incorporated in Delaware and trades on the Nasdaq Capital Market under the symbol RSLS.
Key Financial Metrics
The filing text itself does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are referenced as being detailed in a press release furnished as Exhibit 99.1, which is incorporated by reference but not included in the provided text.
Material Changes
The filing does not provide specific data points to compare against the prior comparable period. It solely indicates that preliminary results for the 2021 fiscal year have been issued.
Guidance, Outlook, and Risks
The document contains no management commentary, forward-looking guidance, or specific risk factors within the text provided. It explicitly states that the information furnished pursuant to Item 2.02 is not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 and is not subject to the liabilities of that section.
Investor Verification Checklist
- Verify the correct registrant name: The filing is for ReShape Lifesciences Inc., not Vyome Holdings, Inc.
- Review Exhibit 99.1 (Press Release dated March 17, 2022) for actual financial figures, as they are absent from the 8-K text.
- Confirm the preliminary nature of the results, as the filing notes these are not audited financial statements.
- Check the Nasdaq Capital Market for the trading symbol RSLS to ensure accurate stock identification.